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Essentials
• Shp2 negatively regulates thrombus stability under pathological shear rate.
• Shp2 suppresses TXA2 receptor-mediated platelet dense granule secretion.
• Through aIIbb3 outside-in signaling, Shp2 targets calmodulin-dependent activation of Akt.
• Shp2 may serve to prevent the formation of unwanted occlusive thrombi.
Summary. Background: Perpetuation is the final phase of thrombus formation; however, its mechanisms and regulation are poorly understood. Objective: To investigate the mechanism of Shp2 in platelet function and thrombosis. Methods and results: We demonstrate that the platelet-expressed Src homology region 2 domain-containing protein tyrosine phosphatase Shp2 is a negative regulator of thrombus stability under high shear stress. In a ferric chloride-induced mesenteric arteriole thrombosis model, megakaryocyte/platelet-specific Shp2-deficient mice showed less thrombi shedding than wild-type mice, although their occlusion times were comparable. In accordance with this in vivo phenotype, a microfluidic whole-blood perfusion assay revealed that the thrombi formed on collagen surfaces by Shp2-deficient platelets were more stable under high shear rates than those produced by wild-type platelets. Whereas Shp2 deficiency did not alter platelet responsiveness towards thrombin, ADP and collagen stimulation, Shp2-deficient platelets showed increased dense granule secretion when stimulated by the thromboxane A 2 analog U46619. Shp2 appears to act downstream of integrin a IIb b 3 outside-in signaling, inhibiting the phosphorylation of Akt (Ser473 and Thr308) and dense granule secretion. Calmodulin was also shown to bind both Shp2 and Akt, linking Shp2 to Akt activation. Conclusions: Platelet Shp2 negatively regulates thrombus perpetuation under high shear stress. This signaling pathway may constitute an important mechanism for the prevention of unwanted occlusive thrombus formation, without dramatically interfering with hemostasis.
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Introduction
In response to vascular injuries, platelets rapidly activate thrombus formation. Platelet thrombus formation can be considered as a phased process of initiation, propagation, and perpetuation [1] [2] [3] . The initiation phase results in the firm adhesion of platelets to the exposed subendothelial matrix proteins on vessel walls. During propagation, additional platelets are recruited from blood flow to support the growth of a thrombus. The final perpetuation phase stabilizes the thrombus [4] . Perturbation or dysregulation of this process causes pathological conditions such as bleeding, infarction, and embolization.
The main mechanisms underlying the initiation and propagation of platelet thrombi are well documented. Collectively, inside-out signaling from collagen receptors [5] [6] [7] , glycoprotein Ib-IX-V [8] and G-protein-coupled receptors (GPCRs) [9] leads to the conformational change of integrin a IIb b 3 [10] [11] [12] . The subsequent high-affinity binding between a IIb b 3 and its ligands [3] brings about platelet-vessel wall adhesion and platelet-platelet aggregation. The regulation of thrombus perpetuation is less well understood. It has been reported that outside-in signaling, which occurs downstream of activated a IIb b 3 , upon ligand engagement, plays an essential role in stabilizing the developing thrombus [13] [14] [15] [16] . Also, molecules accumulated within thrombi, such as ADP [17] , thromboxane A 2 (TXA2) [18] , Gas6 [19] , semaphorin 4D [20] , and ephrins [3, 21] , have been identified as important players in the stabilization of thrombus. Recently, the phosphoinositide 3-kinase (PI3K)-Akt pathway has been established as a central regulator of thrombus stability [17, 22, 23] . However, detailed mechanistic information on how the effects of soluble agonists, rheological change and a IIb b 3 signaling are coordinated during thrombus stabilization is lacking.
Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (Shp2), encoded by PTPN11, is a non-receptor phosphotyrosine phosphatase that is expressed in many vertebrate cells [24, 25] . Shp2 has a well-known role in the regulation of the PI3K and mitogen-activated protein kinase pathways, through its protein tyrosine phosphatase catalytic domain or SH2 regulatory domain [26] [27] [28] . In platelets, Shp2 has been shown to negatively regulate glycoprotein (GP) VI-mediated platelet activation, when recruited by surface receptors such as platelet endothelial cell adhesion molecule-1 [29] and murine paired immunoglobulin-like receptor B [30] . Recently, Shp2 has also been reported to participate in C-type lectin-like receptor 2-elicited and a IIb b 3 -elicited platelet responses [31] . Given the pivotal importance of PI3K and a IIb b 3 in platelet activation and thrombus formation [16, 17, 22] , it seems reasonable to hypothesize that Shp2 may participate in the regulation of platelet plug formation and stability. However, a study employing megakaryocyte/platelet-specific Shp2-deficient mice found no obvious abnormalities in the formation of occlusive thrombi in vivo or platelet aggregation stimulated by GPVI (collagen and collagen-related peptide) or GPCR (ADP and thrombin) agonists in vitro [31] . The possible role of Shp2 in thrombus stability under high-shear conditions has not yet been investigated.
In the current study, using megakaryocyte/platelet-specific Shp2-deficient mice, we demonstrate the role of platelet Shp2 in inhibiting platelet dense granule secretion and in negatively influencing thrombus stabilization under high shear stress. These effects of platelet Shp2 are specifically coupled to TXA2/thromboxane receptor (TP) signaling and are downstream of a IIb b 3 -mediated outside-in signaling, possibly through an interaction with calmodulin and Akt.
Methods
Detailed methods are provided as Data S1.
Results

Shp2 deficiency in platelets increases thrombus stability
Shp2
flox/flox PF4-Cre + (Shp2 À/À ) mice were genotyped by PCR, and ablation of Shp2 in platelets was confirmed by western blotting (Fig. S1A-C) . Platelet-specific Shp2-deficient mice were viable and fertile, and did not show any evident bleeding tendency or thrombotic events over their lifespan. Except for an approximately 13% reduction in platelet counts in Shp2 À/À mice, red blood cell counts, white blood cell counts, hematocrits and hemoglobin concentrations were comparable between Shp2 À/À mice and wild-type (WT) mice (Table S1 ). Surface expression of CD41, CD42b, and GPVI, as determined by flow cytometry, did not differ between Shp2 À/À and WT platelets (Fig. S1D) .
In a ferric chloride-induced mesenteric arteriole injury model, WT and Shp2 À/À mice did not differ in the induction of platelets interacting with the injured vessel wall, the growth of thrombi, and the arteriole occlusion times (Fig. 1A,B) . However, Shp2 À/À mice showed significantly fewer emboli detaching from thrombus than WT mice (1.29 AE 0.34 versus 3.17 AE 0.76 per vessel injury, *P < 0.05; Fig. 1C ; Videos S1 and S2). Thrombus formation and stability were then tested by perfusion of whole blood over an immobilized collagen surface at a high shear rate of 3000 s À1 . Under such conditions, both WT and Shp2 À/À platelets quickly formed thrombi with comparable stability, up to 210 s ( Fig. 1Dii ; Video S3). WT thrombi then became unstable after 210 s of perfusion, as shown by the apparent thrombus relaxation, with only a single platelet layer and small aggregates remaining on the collagen surface at the end of the assay period. In the absence of platelet Shp2, thrombi remained stable or even grew further under continuous perfusion at the (high) shear rate of 3000 s À1 throughout the observation time (≥ 300 s) (Fig. 1D) . Thrombi formed by Shp2 À/À platelets were much denser than those formed by WT platelets, with prominently elevated heights, as viewed from a three-dimensional reconstruction of Zstacked confocal microscopic images (Fig. S2A) . Similar enhanced stability of thrombi formed by Shp2 À/À platelets was observed under even higher-shear conditions (4000 s À1 ) (Fig, S2B ).
To confirm this apparently novel role of platelet Shp2 in the regulation of thrombus stability, WT and Shp2 À/À platelets were perfused at an initial shear rate of 500 s À1 to allow the formation of thrombi, and then at a shear rate of 4000 s
À1
. After 2 min of perfusion at 500 s
, WT and Shp2 À/À platelets formed thrombi with comparable sizes;
the subsequent switch to a shear rate of 4000 s À1 resulted in further growth of thrombi ( Fig. 1Ei ; Video S4). Again, the thrombi formed by Shp2 À/À platelets were more resistant to high shear than those formed by WT platelets ( Fig. 1Eii ; Video S4).
To test the possibility that the enhanced stability of thrombi formed by Shp2 À/À platelets was caused by altered initial platelet adhesion, recombinant whole blood with reduced platelet concentrations (2 9 10 7 mL -1
) was perfused over a collagen surface. Platelets from WT and Shp2 À/À mice adhered with similar efficiency (Fig. S3 ),
indicating that Shp2 is not involved in the regulation of initial platelet adhesion. Thus, Shp2 permits the initial phase of adhesion, but reduces thrombus stability, particularly under high-shear conditions.
Shp2 deficiency enhances U46619-triggered platelet dense granule secretion but not aggregation
To characterize the role of Shp2 in platelet activation, washed platelets were subjected to collagen, thrombin, ADP and TXA2 analog U46619 stimulation. Neither aggregation nor dense granule secretion was found to be defective in Shp2 À/À platelets stimulated with collagen
), Shp2 À/À platelets invariantly showed enhanced dense granule secretion, despite equivalent aggregation rates between Shp2 À/À and WT platelets ( Fig. 2A ). TXA2 typically induced two waves of platelet dense granule secretion, but the enhancement of secretion by Shp2 deficiency was more prominent during the second wave (90 s after simulation) (Fig. 2Ai ). Both waves of secretion and the enhancement by Shp2 deficiency were abolished in the presence of the TXA2 receptor antagonist SQ29584 (Fig. 2B ). In addition, Shp2 deficiency did not affect TXA2-induced a IIb b 3 activation (JON/A binding) or P-selectin expression (Fig. S5 ). These results indicate that Shp2 mediates a specific platelet secretion phenotype downstream of TP. Moreover, the increased thrombus stability resulting from Shp2 deficiency in platelets may also be closely associated with the function of TXA2, in that aspirin dissembled the thrombi formed on an immobilized collagen surface, and eliminated the difference between WT and Shp2 À/À platelets ( Fig. S6 ).
Shp2 deficiency-enhanced platelet secretion is P2Y 12 receptor-dependent and a IIb b 3 activation-dependent
Previous studies have indicated that U46619-triggered platelet dense granule secretion is dependent on ADP, a IIb b 3 activation, and the subsequently produced TXA2 [12, 32] . We thus investigated whether Shp2 deficiencyinduced secretion enhancement in response to U46619 is subject to regulation by the above factors. As shown in Fig. 3 , the P2Y 12 receptor antagonist 2MeSAMP decreased aggregation and abolished U46619-induced secretion in both Shp2 À/À and WT platelets (Fig. 3A,B ).
The P2Y 1 receptor antagonist MRS2179 impaired platelet aggregation and dense granule secretion induced by U46619 in both Shp2 À/À and WT platelets; however,
Shp2
À/À platelets still showed higher second-wave secretion than WT platelets (Fig. 3A) . The cyclooxygenase inhibitor indomethacin also decreased platelet aggregation and the dense granule secretion induced by U46619 in both Shp2 À/À and WT platelets, but indomethacin was unable to abolish the difference in second-wave secretion between Shp2 À/À and WT platelets (Fig. 3A) .
The a IIb b 3 inhibitor tirofiban totally abolished platelet aggregation and second-wave secretion in response to U46619, and thus abolished the secretion difference between Shp2 À/À and WT platelets ( Akt is downstream of Shp2 and responsible for the enhanced secretion in Shp2 À/À platelets stimulated with
U46619
To explore how Shp2 regulates TXA2-induced platelet secretion, the activation of key signals downstream of TP, including phospholipase Cb (PLCb), Src-family kinase, and PI3K-Akt [12] , were assessed in U46619-stimulated WT and Shp2 À/À platelets. Figure 4A demonstrates the temporal changes in phosphorylation of PLCb (Ser1105), Lyn (Tyr507), p85 (Tyr458)/p55 (Tyr199) and Akt (Ser473 and Thr308) after U46619 stimulation. Phosphorylation of PLCb (Ser1105), Lyn (Tyr507) and p85 (Tyr458)/p55 (Tyr199) was not significantly affected by Shp2 deficiency throughout the time period measured (180 s) (Fig. 4A ). However, the phosphorylation level of Akt (Ser473 and Thr308) was found to be significantly higher in Shp2 À/À platelets than in WT platelets; the differences were most obvious at 90 s after stimulation, when second-wave secretion started to occur (Fig. 4Aii) . At 180 s, the phosphorylation levels of Akt (Ser473 and Thr308) were comparable between Shp2 À/À and WT platelets (Fig. 4Aii) . Importantly, the Akt inhibitor SH-6 eliminated the enhancement of Akt phosphorylation (Ser473 and Thr308) (Fig. S7 ) and abolished the enhanced second wave of platelet secretion induced by Shp2 deficiency (Fig. 4B ). These data suggest that Akt is functionally coupled to the secretion phenotype caused by Shp2 deficiency. Moreover, consistent with the dependence of Shp2 deficiencyinduced secretion enhancement on ADP and a IIb b 3 ( Fig. 3) , incubation with tirofiban or apyrase greatly decreased Akt phosphorylation and eliminated the differences in Akt phosphorylation between Shp2 À/À and WT platelets ( Fig. 4C ), supporting a model whereby Akt acts downstream of Shp2.
Shp2 negatively regulates a IIb b 3 outside-in signaling
The effect of tirofiban in eliminating Shp2 deficiencyenhanced platelet second-wave secretion suggests that Shp2 is involved in a IIb b 3 outside-in signaling. Because clot retraction mediated by WT and Shp2 À/À platelets did not differ (Fig. S8A) , platelet spreading on immobilized fibrinogen was utilized to investigate the involvement of Shp2 signaling in this process.
As compared with WT platelets, Shp2 À/À platelets showed enhanced spreading on fibrinogen (Fig. 5Ai) . Although apyrase and aspirin were both able to significantly reduce the spreading areas, only apyrase fully eliminated the spreading difference between Shp2 À/À and WT platelets (Fig. 5Aii) . In fully spread platelets, the phosphorylation levels of the b 3 cytoplasmic domain (Tyr747 and Tyr759), c-Src (Tyr418 and Tyr416) (both refer to the same residue of c-Src) and p38 (Thr180 and Tyr182) were comparable between WT and Shp2 À/À platelets (Fig. 5B) .
However, the phosphorylation levels of Akt (Ser473 and Thr308) and extracellular signal-regulated kinase (ERK) (Thr202 and Tyr204) were significantly increased in Shp2 significantly decreased phosphorylation of b 3 , Src family kinases and p38 in WT and Shp2 À/À platelets, it failed to eliminate the differences in the phosphorylation levels of Akt and ERK between WT and Shp2 À/À platelets (Fig. 5B) , suggesting that activation of Akt and ERK may be upstream of dense granule secretion in platelets spread on immobilized fibrinogen. In contrast to spread platelets, the phosphorylation levels of ERK remained comparable between WT and Shp2 À/À platelets stimulated with U46619, with or without the presence of tirofiban or apyrase (Fig. S8B) . Collectively, whereas Akt activation is consistently increased by Shp2 deficiency under both circumstances (U46619 stimulation and spread on fibrinogen), ERK phosphorylation does not appear to be regulated by Shp2 under conditions of U46619 stimulation.
Shp2 acts through calmodulin to regulate signaling and dense granule secretion
We next sought to identify the molecule(s) interacting with Shp2 during U46619-induced platelet activation. Shp2 did not directly interact with Akt (data not shown).
The activation of PI3K pathway molecules, such as the phosphorylation of p85 (Tyr458)/p55 (Tyr199) (Fig. 4Ai) , phosphoinositide-dependent kinase 1 (Ser241), and mammalian target of rapamycin complex 2 (Ser2448) (data not shown), were not influenced by Shp2 deficiency. Moreover, the complex formed by Shp2-Grb-2-associated binding protein 1 and the p85 regulatory subunit of PI3K [33] , which has been reported to change the subcellular localization of PI3K and diminish GPVI signaling [29] , was not detected when platelets were stimulated with U46619 (Fig. S9A) . U46619-stimulated WT platelet samples were immunoprecipitated with anti-Shp2 antibody and processed for mass spectrometry to identify the possible partners of Shp2 (Fig. S9B ). This method identified 103, 99, 64 and 52 proteins in samples stimulated by U46619 for 0, 60, 90 and 120 s, respectively. After subtraction of the non-specific-binding proteins by comparison with the control IgG-immunoprecipitated data (data not shown), the potential Shp2-binding proteins in the context of U46619-stimulated platelet activation were determined, and are summarized in Table S2 . Among them, Src kinase-associated phosphoprotein 2 (SKAP2) [34] [35] [36] , thrombospondin-1 [37, 38] and calmodulin [39] were selected for further study, given that there is a reported connection of these proteins with a IIb b 3 outsidein signaling.
Immunoprecipitation and western blot analysis confirmed the interaction of SKAP2, calmodulin and thrombospondin-1 with Shp2 in U46619-stimulated platelets ( Fig. 6A; Fig. S9C) . Notably, the Shp2-calmodulin interaction was detected in both U46619-stimulated platelets and platelets spread on fibrinogen (Fig. 6A,B) . In comparison, the Shp2-calmodulin interaction was only weakly induced by thrombin and was essentially absent after stimulation with ADP (Fig. S9D) . These data indicate that the Shp2-calmodulin interaction is TXA2/TP-specific. Importantly, the calmodulin inhibitors W-7 (Fig. 6C ) and W-13 ( Fig. S10A ) not only strongly inhibited WT and Shp2
À/À platelet aggregation and dense granule secretion, but also eliminated the secretion difference between WT and Shp2 À/À platelets. Moreover, W-7 (Fig. 6D ) or W-13 ( and WT platelets, either stimulated with U46619 (Fig. 6E ) or spread on fibrinogen (Fig. 6F) . Unlike what was found in platelets stimulated with U46619, Shp2 deficiency did not affect Akt phosphorylation after ADP or thrombin stimulation, and W-7 equally decreased Akt phosphorylation in WT and Shp2 À/À platelets stimulated with ADP or thrombin (Fig. S11) , providing further evidence that the regulation by Shp2 is TXA2/TP-specific. Intriguingly, calmodulin was found to directly interact with Akt in platelets either stimulated with U46619 (Fig. 6G ) or spread on fibrinogen (Fig. 6H) , and their interaction was enhanced in the absence of Shp2 (Fig. 6G,H) . These experiments are consistent with a model in which calmodulin serves as the signaling bridge between Shp2 and the activation of Akt in platelets.
Discussion
The current study, combining both in vitro and in vivo approaches, has revealed an intriguing role of platelet Shp2 in negatively regulating thrombus stability under high shear stress. In line with the role of TXA2 and ADP in promoting thrombus stability, Shp2 specifically inhibits TXA2-induced platelet dense granule secretion. Moreover, Shp2 acts through a IIb b 3 outside-in signaling-dependent Akt phosphorylation. Calmodulin has also been identified as the potentially critical bridging molecule mediating the effect of Shp2 on Akt activation. These results suggest that platelet Shp2 contributes to the orchestration of key factors in the regulation of thrombus stabilization, including the effects of secondarily generated agonists, rheological change, and a IIb b 3 signaling. Our study reveals a role of platelet Shp2 in inhibiting integrin outside-in signaling-dependent Akt activation and subsequent platelet dense granule secretion; these findings support previous studies indicating that stable thrombi require continuous signaling through the ADP and PI3K pathways [17, 22] . Although ADP and PI3K signaling are also required for the initiation and propagation of thrombi [17, 40] , platelet Shp2 functions selectively to regulate the stability of thrombi. As previously found [31] , Shp2 deficiency in platelets does not appear to affect platelet adhesion or the build-up of thrombi. Several functional features of Shp2 may account for the differential regulation of separate phases of thrombus formation by this molecule. First, as shown by platelet aggregation and JON/A binding results, Shp2 is not involved in inside-out signaling and the activation of a IIb b 3 , so Shp2 deficiency does not prevent intact platelet-vessel wall and platelet-platelet interactions. Second, Shp2 only influences a IIb b 3 outside-in signaling-dependent ADP secretion; ADP secretion through inside-out signaling may still suffice for recruitment of additional platelets to support the growth of thrombi. Third, it is possible to envisage a need for Shp2 to reduce the stability of thrombi under high shear stress at the perpetuation stage of thrombosis, when a vessel lumen may be at risk of being occluded by a thrombus [41] . Previous studies have identified a platelet signaling network that positively regulates thrombus stabilization and ensures efficient hemostasis [3] ; the current findings further extend this network by showing that platelets are also endowed with a negative regulation mechanism specific for thrombus stability, which, under elevated shear stresses, may prevent dangerous occlusive thrombus formation.
Vascular thrombi consist of a closely packed core and a loosely associated shell [41] . In the current study, Shp2 deficiency in platelets results in preservation of the integrity of the whole thrombus under high shear stress, whereas high shear flows clearly remove the bulk of shell region of thrombi formed by WT platelets (Video S4). This indicates that Shp2 mainly regulates the stability of the shell region of the thrombus. Coinciding with the findings that the shell region of the thrombus is influenced by ADP or TXA2 [18] and the core is under the regulation of thrombin [41, 42] , Shp2 selectively modulates TXA2-stimulated platelet dense granule secretion, but not platelet responses evoked by thrombin. Moreover, Shp2 responds to TXA2 stimulation by regulating outside-in signaling, consistent with the previous report that TXA2 relies on integrin outside-in signaling to regulate platelet dense granule secretion [32] . Interestingly, Shp2 deficiency is associated with an increase in late outside-in signaling (e.g. phosphorylation of Akt and ERK [43, 44] ), but intact early outside-in signaling (signified by phosphorylation of the b 3 cytoplasmic domain and c-Src [45, 46] ). Because alterations in early outside-in signaling (such as phosphorylation of c-Src) are characteristic of thrombin receptorpromoted integrin outside-in signaling [13] , the regulation pattern of Shp2 (only influencing late outside-in signaling) further dissociates Shp2 from the pathways mediated by thrombin receptors. Thus, Shp2 may serve as a signal to distinguish the pathway initiated by TP from that initiated by protease-activated receptor 4, although both GPCRs share common downstream G-proteins (Ga q and Ga 12/13 ) to regulate platelet activation [12, [47] [48] [49] [50] .
This study not only confirms the previous report that Shp2 downregulates a IIb b 3 outside-in signaling [31] , but also reveals an intriguing pathway that Shp2 utilizes to specifically inhibit a IIb b 3 outside-in signaling-mediated platelet dense granule secretion. By combining the molecular and functional approaches, we have shown that Shp2 may contribute to the activation of Akt, which is a protein that is critically involved in platelet secretion and activation [43, 51, 52] . Our experiments also show that calmodulin forms distinct complexes with Shp2 and Akt, and that Shp2 deficiency enhances the interaction between calmodulin and Akt. Binding between calmodulin and Akt has been reported in cancer cells [53] , in which the association of calmodulin and the Akt pleckstrin homology domain helps to shuttle Akt to the plasma membrane and facilitate its activation by conventional PI3K pathway proteins [54, 55] . The PI3K pathway itself does not appear to be regulated by Shp2 in platelets, as corroborated by the data showing that neither the activity nor the subcellular localization of PI3Ks is influenced by Shp2 deficiency. Rather, PI3Ks work upstream of Shp2 regulation, because inhibition of PI3Ks abolishes the secretion change induced by Shp2 deficiency (Fig. S12) . Therefore, downstream of a IIb b 3 outside-in signaling, Shp2 may serve to sequester calmodulin via the formation of an Shp2-calmodulin complex, thereby reducing the availability of calmodulin for binding to and facilitating the activation of Akt. Interestingly, the catalytic activity of Shp2 may not be necessary for the binding of Shp2 and calmodulin, as shown by the failure to influence the association of Shp2 and calmodulin in platelets stimulated with U46619 of the Shp2 inhibitor PHPS1 (Fig. S13) , which specifically enables silencing of the catalytic activity of Shp2 [56] .
Although a previous study has elegantly profiled the landscape of the role of Shp2 in megakaryocyte development, and platelet production and function [31] , our present study has further revealed the functions and signaling mediated by Shp2 in platelets. The role of Shp2 in platelet function identified here, including platelet responses induced by GPVI and a IIb b 3 , correlates well with the findings from the previous study. It is worth mentioning that Shp2 flox/flox mice in the previous study were generated by engineering loxP sites flanking exon 11 of Shp2 [57] , whereas the Shp2 flox/flox mice in the current study were generated by engineering loxP sites flanking exon 4. Although both models achieved total deletion of Shp2 in platelets, it remains to be determined whether there might be a difference in megakaryocyte development between these two models. The current study reveals a 'well-hidden' function of Shp2 in platelets, as the expression of major surface receptors and responsiveness to stimulation are nearly intact for Shp2 À/À platelets. This is in sharp contrast to the phenotype of the megakaryocyte/platelet-specific Shp1/Shp2 double knockout (DKO) platelets, which show severely reduced expression of surface receptors and drastically compromised reactivities [31] . Apart from the indication that Shp1 and Shp2 are both required for thrombocytogenesis, the dramatic difference between the responsiveness of Shp2 À/À platelets and that of DKO platelets might also reflect redundant regulation of platelet function by Shp1 and Shp2. Indeed, both Shp1 and Shp2 are critically influenced by an important common upstream regulator, the ITIM-containing receptor G6b-B, which in itself has become a recent research focus in the field [58] .
In summary, we have demonstrated a hitherto unidentified role of platelet Shp2 in suppressing thrombus stability under high shear stress. Through reducing the calmodulin-Akt association and thereby Akt activation, Shp2 inhibits TXA2-mediated and a IIb b 3 outside-in signaling-mediated dense granule secretion. Shp2 thus constitutes an important mechanism for the prevention of the formation of dangerous occlusive thrombi, without interfering with essential hemostasis. 
